Sensitivity analysis for patients treated with the cilostazol-based combination
| Crude HR (95% CI) | P value | Adjusted HR (95% CI) | P value | IPTW,* weighted HR (95% CI) | P value | |
| Primary outcome | ||||||
| Cilostazol-based combination | 1 (ref.) | 1 (ref.) | 1 (ref.) | |||
| Aspirin monotherapy | 0.97 (0.77 to 1.22) | 0.79 | 1.14 (0.90 to 1.44) | 0.27 | 0.99 (0.71 to 1.39) | 0.97 |
| Clopidogrel–aspirin | 0.87 (0.69 to 1.10) | 0.24 | 0.89 (0.71 to 1.13) | 0.34 | 0.78 (0.56 to 1.08) | 0.14 |
| All strokes | ||||||
| Cilostazol-based combination | 1 (ref.) | 1 (ref.) | 1 (ref.) | |||
| Aspirin monotherapy | 0.91 (0.73 to 1.15) | 0.44 | 1.08 (0.85 to 1.36) | 0.55 | 0.93 (0.67 to 1.30) | 0.67 |
| Clopidogrel–aspirin | 0.82 (0.65 to 1.04) | 0.10 | 0.84 (0.67 to 1.07) | 0.16 | 0.73 (0.52 to 1.02) | 0.07 |
| All-cause mortality | ||||||
| Cilostazol-based combination | 1 (ref.) | 1 (ref.) | 1 (ref.) | |||
| Aspirin monotherapy | 7.70 (1.08 to 55.09) | 0.04 | 9.16 (1.26 to 66.44) | 0.03 | 15.75 (2.18 to 113.77) | 0.006 |
| Clopidogrel–aspirin | 6.79 (0.95 to 48.80) | 0.06 | 6.68 (0.92 to 48.48) | 0.06 | 11.67 (1.61 to 84.53) | 0.02 |
| MI† | ||||||
| Cilostazol-based combination | 1(ref.) | |||||
| Aspirin monotherapy | 1.75 (0.09 to 32.65) | 0.71 | Non-estimable | Non-estimable | ||
| Clopidogrel–aspirin | 2.92 (0.16 to 53.48) | 0.47 | Non-estimable | Non-estimable |
Adjusted variables: age; male sex; initial NIHSS score; arrival time; TOAST classification; history of TIA, stroke, CAD and PAD; HTN; DM; dyslipidaemia; smoking; atrial fibrillation; prior antiplatelet, antihypertensive, antidiabetic, statin or lipid-lowering agent use; multiple lesions; LASO; discharge medications of antihypertensives, antidiabetics, statins and lipid-lowering agents; creatinine; haemoglobin; platelet count; LDL cholesterol; glucose; and SBP.
*Weighted Cox proportional hazards model with robust standard errors.
†Cox proportional hazards regression using Firth’s penalised maximum likelihood method.
CAD, coronary artery disease; DM, diabetes mellitus; HTN, hypertension; IPTW, inverse probability of treatment weighting; LASO, large artery stenosis/occlusion; LDL, low-density lipoprotein; LDL, low-density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; PAD, peripheral artery disease; TIA, transient ischemic attack; TOAST, Trial of Org 10 172 in Acute Stroke Treatment.